Mr. Tomsicek is CFO of Crispr Therapeutics and brings over 20 years of corporate and financial leadership experience to Milestone. Prior to joining CRISPR, he served as the Chief Financial Officer of Abiomed, a leading medical device company developing and commercializing products to aid in circulatory support.
Andrew Saik joined the Milestone Pharmaceuticals board of directors in July 2024. Mr. Saik has more than 25 years of biopharma finance experience and has participated in over 40 successful mergers and acquisition transactions.
Dr. Pasternak has served as a member of Milestone’s board of directors since November 2019. He is currently a Clinical Professor at the Weill Cornell Medical College.
Mr. Oliveto has served as Milestone’s President and Chief Executive Officer since March 2017 and as a member of Milestone’s board of directors since July 2017. Prior to Milestone Pharmaceuticals, Mr. Oliveto was President, CEO and a Director of Chelsea Therapeutics International, Ltd.
Ms. Liebert has served as a member of Milestone’s board of directors since June 2015. Ms. Liebert served as a Principal of Domain Associates, LLC, a healthcare venture capital firm with an exclusive focus on life sciences, since 2007, and has served as a Managing Director since January 2014.
Mr. Truex has served as a member of Milestone’s board of directors since February 2012, serving as Chairman from June 2012 to October 2018.
Mr. Fischer joined the Milestone Pharmaceuticals Board of Directors in March 2023. He brings to the Board nearly 40 years of experience serving in key leadership positions in the pharmaceutical and medical device industry.
Stuart Duty joined the Milestone Pharmaceuticals board of directors in July 2024. Mr. Duty is an experienced financial executive with over 30 years in finance and investment banking, building leading healthcare teams on multiple platforms with a history of substantial growth in both revenue and personnel.
Robert J. Wills, PhD has been a member of our Board of Directors since October 2020. He has over three decades of experience as a leader in the pharmaceutical industry.
.png){kind=small}